Abiola Ibraheem

Abiola Ibraheem

UNVERIFIED PROFILE

Are you Abiola Ibraheem?   Register this Author

Register author
Abiola Ibraheem

Abiola Ibraheem

Publications by authors named "Abiola Ibraheem"

Are you Abiola Ibraheem?   Register this Author

7Publications

124Reads

39Profile Views

Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?

Cancer 2019 01 2;125(2):213-222. Epub 2018 Nov 2.

Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31818
Publisher Site
http://dx.doi.org/10.1002/cncr.31818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329644PMC
January 2019

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

J Clin Oncol 2018 05 28;36(14):1389-1395. Epub 2018 Mar 28.

Russell Z. Szmulewitz, Abiola Ibraheem, Elia Martinez, Mark F. Kozloff, Chadi Nabhan, Theodore Karrison, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago; Mark F. Kozloff, Ingalls Hospital, Harvey; Paul Fishkin, Illinois Cancer Care, Peoria, IL; Cody J. Peer and William D. Figg, National Cancer Institute, Rockville, MD; Bradley Carthon and R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA; and Wei Peng Yong and Edmund Chiong, National University Cancer Institute, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.4381
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.4381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941614PMC
May 2018

Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.

Breast Cancer Res Treat 2018 Feb 27;168(1):207-220. Epub 2017 Nov 27.

Department of Public Health Sciences, The University of Chicago, 5841 S. Maryland Ave., MC2000, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4587-8DOI Listing
February 2018

Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes.

Cancer 2017 12 26;123(24):4752-4756. Epub 2017 Oct 26.

University of Chicago Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31073DOI Listing
December 2017

SIRFLOX: Progression-Free Survival in the Liver As a Surrogate End Point for Survival?

J Clin Oncol 2016 12 30;34(34):4193. Epub 2016 Sep 30.

Adeola O. Ayoola, The Calvary Mater Hospital, Newcastle, New South Wales, Australia; and Abiola F. Ibraheem, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.3523DOI Listing
December 2016

Re: Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

J Natl Cancer Inst 2014 Sep 29;106(9). Epub 2014 Sep 29.

Morehouse School Of Medicine, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju253DOI Listing
September 2014